FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

$\sim$	AP	ᇚ	A١	/ N I

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person     Farrell Michael J.			2. Issuer Name and Ticker or Trading Symbol RESMED INC [ RMD ]		tionship of Reporting all applicable) Director	to Issuer	
(Last) (First) (Middle) RESMED INC.		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022		Officer (give title below)  Chief Executive O		Other (specify below)
9001 SPECTRUM CENTER BLVD  (Street)  SAN DIEGO CA 92123		92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person			
(City)	(State)	(Zip)					

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Of (D) (Instr. 3		A) or Disposed	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
ResMed Common Stock	06/15/2022		<b>M</b> <sup>(1)</sup>		5,675	A	\$57.76	410,935	D	
ResMed Common Stock	06/15/2022		S <sup>(1)</sup>		5,675	D	\$202.5392(2)	405,260	D	
ResMed Common Stock								3,880	I	Lisette and Michael Farrell Foundation
ResMed Common Stock								5,090	I	Lisette and Michael Farrell Family Trust

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported		11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$57.76	06/15/2022		M			5,675	11/11/2017 <sup>(3)</sup>	11/16/2023	ResMed Common Stock	5,675	\$0	99,940	D	

## Explanation of Responses:

- 1. The transaction was conducted under a Rule 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$199.47 to \$206.01. The price reported above reflects the weighted average sale price.
- 3. Represents date options first became exercisable. Options vest 1/3 per year.

Michael J. Farrell, Chief 06/16/2022 Executive Officer

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.